InvestorsHub Logo
Followers 829
Posts 119632
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Tuesday, 10/16/2018 8:05:57 PM

Tuesday, October 16, 2018 8:05:57 PM

Post# of 1051
JNJ reports 3Q18 results—raises 2018 EPS guidance slightly:

https://finance.yahoo.com/news/johnson-johnson-reports-2018-third-104000925.html
http://www.investor.jnj.com/common/download/download.cfm?companyid=JNJ&fileid=984220&filekey=53A55D60-0F98-4481-997B-6F1860D63EC7&filename=Sales_of_Key_Products_Franchises_3Q2018.pdf

…the Company increased its adjusted [i.e. non-GAAP] earnings guidance for full-year 2018 to a range of $8.13 to $8.18 per share. This reflects an increase in expected operational EPS growth to a range of 9.3% to 10.0%.

The old guidance range was $8.07-8.17.

Oncology sales—especially Zytiga, Darzelex and Imbruvica—powered the quarterly results.

Additional links:

https://www.wsj.com/articles/johnson-johnson-raises-profit-outlook-following-higher-sales-1539690522

https://finance.yahoo.com/news/johnson-johnson-jnj-q3-2018-191229148.html (CC transcript)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent JNJ News